Please provide your email address to receive an email when new articles are posted on . The FDA approved mitapivat for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency.

Topline results from the RISE UP phase 3 trial demonstrated that mitapivat significantly improved hemoglobin response in patients with sickle cell disease.

Diversity, equity, and inclusion (DEI) champions: Lessons learned and implications for future programming to support cancer clinical trials. This is an ASCO Meeting Abstract from the 2023 ASCO Annual ...

Lung cancer, notorious for its high mortality rates, is a leading cause of cancer-related deaths globally, with metastasis being the primary contributor to poor patient outcomes. A critical factor in ...

Pyruvate is produced by glycolysis, a process in which carbohydrates are broken down to create energy. Calcium pyruvate is a popular supplement that many people use primarily for its purported weight ...